Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PDE1A | P54750 | 1/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6348685 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP2C19CYP3A4PDE5A | |
| SCHEMBL6352844 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP2C19CYP3A4PDE5A | |
| SCHEMBL4707209 | 0.86 | GAA (0.40) | GAAADORA1ADORA2AADORA2B | |
| SCHEMBL4707211 | 0.86 | GAA (0.40) | GAAADORA1ADORA2AADORA2B | |
| SCHEMBL6356975 | 0.84 | PABPC1 (0.60) | ALDH1A1CYP1A2CYP2C19CYP3A4PDE5A | |
| SCHEMBL6356972 | 0.83 | PABPC1 (0.45) | ALDH1A1CYP2C19TSHRADORA1ADORA2A | |
| SCHEMBL4707005 | 0.83 | ADORA1 (0.37) | ALDH1A1CYP1A2CYP2C19CYP3A4PDE5A | |
| SCHEMBL4707001 | 0.83 | ADORA1 (0.37) | ALDH1A1CYP1A2CYP2C19CYP3A4PDE5A | |
| SCHEMBL4708435 | 0.81 | PDE4A (0.60) | CYP1A2CYP3A4PDE5ATSHRPDE1A | |
| SCHEMBL4708430 | 0.81 | PDE4A (0.60) | CYP1A2CYP3A4PDE5ATSHRPDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171442-B1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6878715-B1 | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same | CELL THERAPEUTICS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050049262-A1 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same | CELL THERAPEUTICS, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| EP-1171442-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061583-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049262-A1 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same | IL2, CCR10, CCR1 | ALDH1A1 1906/4885CYP1A2 3217/4885CYP2C19 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.